2. Search Result
Search Result
Results for "

Acute myocardial infarction

" in MedChemExpress (MCE) Product Catalog:

51

Inhibitors & Agonists

6

Biochemical Assay Reagents

4

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Isotope-Labeled Compounds

5

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108865
    Alteplase

    Actilyse; Activase

    		 Ser/Thr Protease Cardiovascular Disease Cancer
    Alteplase (Actilyse; Activase), a tissue plasminogen activator prepared by recombination, is a thrombolytic agent that play important roles in acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters .
    The product size below only indicate the effective content of Alteplase. The ratio of Alteplase effective content : total content = 1:46-1:50. The actual ratio depends on the batch.)
    Alteplase
  • HY-B1770
    Sodium Iodide,99%

    		Environmental Pollutants Biochemical Assay Reagents Cardiovascular Disease Endocrinology
    Sodium Iodide is a compound composed of sodium ions and iodine ions. Sodium Iodide scavenges hydrogen peroxide. Sodium Iodide maintains the level of thyroid hormone T3 through its iodine component. Sodium Iodide protects tissues from oxidative damage and regulates thyroid homeostasis. Sodium Iodide relieves acute myocardial infarction .
    Sodium Iodide,99%
  • HY-N0712
    Typhaneoside
    3 Publications Verification

    		 Autophagy mTOR Akt FXR Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Typhaneoside is an orally bioavailable signal modulator and cellular regulator. Typhaneoside regulates the PI3K/Akt/mTOR autophagy transduction pathway. Typhaneoside promotes the activation of AMP-activated protein kinase and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, and cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside activates the farnesoid X receptor signaling pathway, improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside is applicable to research related to post-myocardial infarction heart failure, acute myeloid leukemia, non-alcoholic fatty liver disease, and neurological disorders .
    Typhaneoside
  • HY-153999A
    Rondaptivon pegol sodium

    BT200 sodium

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) sodium is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol sodium effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol sodium inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol sodium can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol sodium
  • HY-112205
    RR-11a
    3 Publications Verification

    		 Legumain Cancer
    RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI) .
    RR-11a
  • HY-10081
    GS-6201
    1 Publications Verification

    CVT-6883

    		 Adenosine Receptor Inflammation/Immunology
    GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM) . GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse . GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice .
    GS-6201
  • HY-168894
    CT-1

    		Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .
    CT-1
  • HY-114869
    DPQ
    3 Publications Verification

    		 PARP Neurological Disease Cancer
    DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
    DPQ
  • HY-B1067
    Antazoline hydrochloride

    Phenazoline hydrochloride

    		 Histamine Receptor HBV Neurological Disease Endocrinology
    Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV .
    Antazoline hydrochloride
  • HY-B0384
    Temocapril hydrochloride
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril hydrochloride
  • HY-106262B
    Delcasertib hydrochloride
    3 Publications Verification

    KAI-9803 hydrochloride; BMS-875944 hydrochloride

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) hydrochloride is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) hydrochloride could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib hydrochloride
  • HY-W011082
    NLRP3-IN-2

    		NOD-like Receptor (NLR) Cardiovascular Disease
    NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism .
    NLRP3-IN-2
  • HY-100713
    Temocapril
    2 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril
  • HY-117970
    MMPI-1154

    		MMP Cardiovascular Disease
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively .
    MMPI-1154
  • HY-107335
    Aplodan

    Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate

    		 Biochemical Assay Reagents Cardiovascular Disease
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-106262
    Delcasertib

    KAI-9803; BMS-875944

    		 PKC Cardiovascular Disease Inflammation/Immunology
    Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. Delcasertib (KAI-9803) could ameliorate injury associated with ischemia and reperfusion in animal models of acute myocardial infarction (MI) .
    Delcasertib
  • HY-153999
    Rondaptivon pegol

    BT200

    		 Integrin Apoptosis Cardiovascular Disease Inflammation/Immunology
    Rondaptivon pegol (BT200) is an aptamer targeting von Willebrand factor (VWF), with an EC50 of 33 nM in humans. Rondaptivon pegol effectively alleviates acute myocardial ischemia-reperfusion injury in mice by inhibiting VWF activity, reducing microvascular obstruction, inflammatory responses and cardiomyocyte apoptosis (apoptosis). Rondaptivon pegol inhibits the binding of VWF to platelet glycoprotein GPIb, thereby preventing arterial thrombosis in cynomolgus monkeys. Rondaptivon pegol can be used in research related to arterial thrombosis, stroke, myocardial infarction and myocardial ischemia-reperfusion injury .
    Rondaptivon pegol
  • HY-174935
    DBCO-PEG1000-NHS

    		Biochemical Assay Reagents Others
    DBCO-PEG1000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material .
    DBCO-PEG1000-NHS
  • HY-N11222
    Nonanoylcarnitine

    C9 carnitine

    		 Endogenous Metabolite Cardiovascular Disease Cancer
    Nonanoylcarnitine is a metabolite associated with chronic environmental exposure to polycyclic aromatic hydrocarbons (PAH) and fragmented QRS waves in acute myocardial infarction. Nonanoylcarnitine can be used as a potential biomarker for the metabolic outcome of PAH exposure and the prognosis of acute myocardial infarction .
    Nonanoylcarnitine
  • HY-110067
    VO-OHPic

    		PTEN Apoptosis Autophagy Ferroptosis Reactive Oxygen Species (ROS) Interleukin Related Akt Keap1-Nrf2 Cardiovascular Disease Inflammation/Immunology Cancer
    VO-OHPic is a reversible, noncompetitive PTEN inhibitor with an human IC50 value of 46 nM. VO-OHPic inhibits PTEN signaling, activates Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance and elevates IL-10 levels. VO-OHPic inhibits autophagy, ferroptosis and oxidative stress. VO-OHPic can be used for the research of acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy and cancer .
    VO-OHPic
  • HY-142059
    PDE5-IN-4

    		Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .
    PDE5-IN-4
  • HY-B1067A
    Antazoline

    Phenazoline

    		 Histamine Receptor Neurological Disease Endocrinology
    Antazoline (Phenazoline) is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline has anti-arrhythmic effect in acute myocardial infarctions. Antazoline can be studied in research for cardiovascular diseases, and HBV .
    Antazoline
  • HY-174935A
    DBCO-PEG2000-NHS

    		Biochemical Assay Reagents Others
    DBCO-PEG2000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material .
    DBCO-PEG2000-NHS
  • HY-160210
    BAY-6096

    		Adrenergic Receptor Cardiovascular Disease
    BAY-6096, a chemical probe, is a potent, selective, and highly water-soluble adrenergic receptor α2B antagonist with an IC50 of 14 nM. BAY-6096 can effectively reduceα 2B receptor agonist-induced rat vascular contraction .
    BAY-6096
  • HY-W040176
    N-PTyrosine PA ammonium

    N-Palmitoyl-tyrosine phosphoric acid ammonium

    		 LPL Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology
    N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a lysophosphatidic acid (LPA) receptor modulator, which exhibits weak inhibitory activity against LPA1 and partial agonist properties towards LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .
    N-PTyrosine PA ammonium
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-175675
    P2Y1 antagonist 4

    		P2Y Receptor Keap1-Nrf2 Cardiovascular Disease Neurological Disease
    P2Y1 antagonist 4 is a selective P2Y1 receptor antagonist with excellent blood-brain barrier (BBB) penetration. P2Y1 antagonist 4 inhibits P2Y1 receptor-mediated cytosolic Ca 2+ increase (IC50 = 1.95 μM) and platelet aggregation (IC50 = 3.24 μM) induced by ADP in rabbit washed platelets. P2Y1 antagonist 4 significantly upregulates the level of nuclear Nrf2 protein in H2O2-treated HT22 cells. P2Y1 antagonist 4 reduces myocardial infarct size in a mouse acute myocardial infarction (MI) model. P2Y1 antagonist 4 can be used for the study of ischemic stroke and myocardial infarction .
    P2Y1 antagonist 4
  • HY-P1129
    AR-M1896

    		Neuropeptide Y Receptor Neurological Disease
    AR-M1896 is a GalR2 selective agonist with a binding IC50 of 1.76 nM for rat GalR2. AR-M1896 can be used for the research of acute myocardial infarction and neuropathic pain .
    AR-M1896
  • HY-106058
    NCO-700

    		Cathepsin Apoptosis Cardiovascular Disease Cancer
    NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC50 values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors .
    NCO-700
  • HY-174935C
    DBCO-PEG5000-NHS

    		Biochemical Assay Reagents Others
    DBCO-PEG5000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material .
    DBCO-PEG5000-NHS
  • HY-100713R
    Temocapril (Standard)

    		Reference Standards Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril (Standard)
  • HY-100713S
    Temocapril-d5

    		Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril-d5
  • HY-10313
    ZD 2486

    		Integrin Cardiovascular Disease
    ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures [1]
    ZD 2486
  • HY-N13218
    Pueraria Extract

    		Others Cardiovascular Disease
    Pueraria Extract is a kudzu extract, and its components include: Isoflavones. Pueraria Extract (ethanol extract) can significantly improve cardiac damage in rats with acute myocardial infarction. Pueraria Extract improves bile acid levels by increasing the expression of CYP7A1 and restoring the diversity of intestinal microbiota. Pueraria Extract can also inhibit the FXR-FGF15 signaling pathway and increase the expression of OST-α to increase bile acid reabsorption and fecal excretion. .
    Pueraria Extract
  • HY-W424851
    DPQ hydrochloride

    6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride

    		 PARP Infection Inflammation/Immunology
    DPQ hydrochloride is a blood-brain barrier permeable and selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ hydrochloride inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ hydrochloride can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
    DPQ hydrochloride
  • HY-19310
    AMP-579

    		Adenosine Receptor Cardiovascular Disease Metabolic Disease
    AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2A receptors (with Ki values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a Ki value of 56 nM for the A2A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2A receptors (with an IC50 of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .
    AMP-579
  • HY-P991895
    PLG-101

    		Transmembrane Glycoprotein Cardiovascular Disease
    PLG-101 is a human anti-CD8 antibody. PLG-101 can be used in research on acute myocardial infarction .
    PLG-101
  • HY-B1067AR
    Antazoline (Standard)

    Phenazoline (Standard)

    		 Reference Standards Histamine Receptor Neurological Disease Endocrinology
    Antazoline (Phenazoline) (Standard) is the analytical standard of Antazoline. This product is intended for research and analytical applications. Antazoline is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline has anti-arrhythmic effect in acute myocardial infarctions. Antazoline can be studied in research for cardiovascular diseases, and HBV .
    Antazoline (Standard)
  • HY-B1067R
    Antazoline hydrochloride (Standard)

    Phenazoline hydrochloride (Standard)

    		 Reference Standards Histamine Receptor HBV Neurological Disease Endocrinology
    Antazoline (hydrochloride) (Standard) is the analytical standard of Antazoline (hydrochloride). This product is intended for research and analytical applications. Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV .
    Antazoline hydrochloride (Standard)
  • HY-B1067BR
    Antazoline phosphate (Standard)

    Phenazoline phosphate (Standard)

    		 Reference Standards Histamine Receptor Neurological Disease Endocrinology
    Antazoline (phosphate) (Standard) is the analytical standard of Antazoline (phosphate). This product is intended for research and analytical applications. Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV .
    Antazoline phosphate (Standard)
  • HY-B1067B
    Antazoline phosphate

    Phenazoline phosphate

    		 Histamine Receptor Neurological Disease Endocrinology
    Antazoline phosphate is an H1 receptor antagonist that affects the activity of the central nervous system, has a potent antiarrhythmic effect . Antazoline phosphate is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline phosphate can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline phosphate can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline phosphate can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline phosphate also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline phosphate has anti-arrhythmic effect in acute myocardial infarctions. Antazoline phosphate can be studied in research for cardiovascular diseases, and HBV .
    Antazoline phosphate
  • HY-174935B
    DBCO-PEG3400-NHS

    		Biochemical Assay Reagents Others
    DBCO-PEG3400-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material .
    DBCO-PEG3400-NHS
  • HY-174935D
    DBCO-PEG10000-NHS

    		Biochemical Assay Reagents Others
    DBCO-PEG10000-NHS is a dibenzocyclooctyne-conjugated polyethylene glycol derivative bearing an NHS group. DBCO-PEG-NHS forms a stable covalent linkage with the amino group of target molecules via the NHS ester at one end, while introducing a DBCO group at the other end, thus preparing for subsequent click chemical conjugation with any azide-bearing molecule or material .
    DBCO-PEG10000-NHS
  • HY-10081R
    GS-6201 (Standard)

    CVT-6883 (Standard)

    		 Adenosine Receptor Reference Standards Inflammation/Immunology
    GS-6201 (Standard) is the analytical standard of GS-6201 (HY-10081). This product is intended for research and analytical applications. GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM) . GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse . GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice .
    GS-6201 (Standard)
  • HY-160637
    Lp-PLA2-IN-17

    		Phospholipase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Lp-PLA2-IN-17 (Compound 39) is an inhibitor of Lp-PLA2. Lp-PLA2-IN-17 can be used to study disorders involving the hydrolysis of oxidized lipids into two inflammatory substances with the participation of Lp-PLA2 .
    Lp-PLA2-IN-17
  • HY-B0384R
    Temocapril hydrochloride (Standard)

    		Angiotensin-converting Enzyme (ACE) Reference Standards Cardiovascular Disease
    Temocapril (hydrochloride) (Standard) is the analytical standard of Temocapril (hydrochloride). This product is intended for research and analytical applications. Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril hydrochloride (Standard)
  • HY-113769
    WB 3559 A

    		PAI-1 Cardiovascular Disease
    WB 3559 A is a fibrinolytic plasminogen activator. WB 3559 A accelerates the conversion of plasminogen to plasmin and directly degrades fibrin in thrombi. WB 3559 A is promising for research of acute thrombotic diseases (e.g., myocardial infarction, pulmonary embolism) .
    WB 3559 A
  • HY-112071A
    Prenalterol hydrochloride

    		Adrenergic Receptor Endocrinology
    Prenalterol hydrochloride is a partial adrenal agonist with functional β1-receptor specificity and positive inotropic effects. Prenalterol hydrochloride is effective in suppressing acute heart failure, low output syndrome after myocardial infarction, shock, and reducing orthostatic hypotension in Shy-Drager syndrome .
    Prenalterol hydrochloride
  • HY-107335R
    Aplodan (Standard)

    Creatinol O-phosphate (Standard); Creatinol phosphate (Standard); Creatinolfosfate (Standard)

    		 Biochemical Assay Reagents Reference Standards Cardiovascular Disease
    Aplodan (Standard) (Creatinol O-phosphate (Standard)) is the analytical standard of Aplodan (HY-107335). This product is intended for research and analytical applications. Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan (Standard)
  • HY-105439A
    Clofilium phosphate

    LY 150378

    		 Drug Derivative Cardiovascular Disease
    Clofilium phosphate (LY 150378) is an antiarrhythmic/antifibrillatory agent. Clofilium phosphate significantly prolongs the action potential duration and effective refractory period of canine cardiac Purkinje fibers, increases the ventricular fibrillation threshold, reduces the risk of reentrant arrhythmias, and enables spontaneous conversion of some ventricular fibrillation episodes to sinus rhythm. Clofilium phosphate is applicable to research related to ventricular fibrillation, arrhythmias, and ventricular tachyarrhythmias .
    Clofilium phosphate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: